A Prospective, Open-Label Comparison of Tamsulosin plus &lt;b&gt;&lt;i&gt;Serenoa repens&lt;/i&gt;&lt;/b&gt; and Bovine Colostrum versus Tamsulosin Alone in the Treatment of Benign Prostatic Hyperplasia

Maida, Fabrizio Di; Mari, Andrea; Rubino, Roberta; Carini, Marco; Siena, Giampaolo

doi:10.1159/000503735

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another matched findings to the current study, the efficacy of both the Saw Palmetto and tamsulosin groups from day 0 to 6th month of treatment produced similar the mean changes Qmax in both, and the decreased prostate volume andthe improvement in PVR was noticed in the Saw Palmetto group the most.Additionally, in his review Giacomo N. reported superiority issue of the combination of Permixon and tamsulosin for relieving LUTS (p < 0.01) but not in reducing the number of nocturnal voids and increasing Qmax which was explored more in Permixon alone [37] . Inversely, prospective open-label, 12-month study stated no differences in maximal urinary flow rate, PVR, prostate-specific antigen, and prostate volume between a combination of (Saw Palmetto with bovine colostrums) [19] .…”

Section: Discussionmentioning

confidence: 96%

Saw Palmetto Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Assessment in Iraq

Mazin Abdulridha Ateyah,

Manal Khalid Abdulridha,

Munaim Jumaa Alkabee

2021

MLU

View full text Add to dashboard Cite

Background: The current study was designed to explore the effectiveness of Saw Palmetto as monotherapy or supplementation with tamsulosin in the treatment of patients with lower urinary tract symptoms consistent with benign prostatic hyperplasia. Method: The present study is diagnosed patient with moderate to severe symptomatic BPH. (60) Patients were divided into 3 groups; Group (1) treated with Saw Palmetto cap (320 mg); Group (2) treated with Saw Palmetto cap (320 mg) and tamsulosin (0.4mg); Group (3) treated with tamsulosin (0.4mg), daily for 3 months. The assessment is done based on the change in urological IPSS, urodynamic activity, urine flow, voiding quantity measures, and prostate volume. Also, some measurement such as erection function, urinary incontinence, sleeps quality, and quality of life. Results: Saw Palmetto supplementation with tamsulosin revealed a significant decrease in the IPSS score(P<0.01), a significant increase in the urine flow rate and the voided volume, a significant decrease in the post-void residual volume and prostate volume (P<0.01),and decrease in serum PSA level (P<0.01). Additionally, improved erection function decreased urinary incontinence score, improvement in sleep quality, and improvement in the quality of life score among the Saw Palmetto supplementation group was noticed (P˂0.01). Conclusion: The phytotherapy with saw palmetto alone or as supplement collectively produced marked improvement in objective and subjective measurements in men with lower urinary tract symptoms consistent with BPH:

show abstract

Section: Discussionmentioning

confidence: 96%

Saw Palmetto Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Assessment in Iraq

Mazin Abdulridha Ateyah,

Manal Khalid Abdulridha,

Munaim Jumaa Alkabee

2021

MLU

View full text Add to dashboard Cite

show abstract

“…47 SPE + Selenium + Lycopene in combination with tamsulosin is more efficacious than single therapies in improving IPSS and increasing maximal urinary flow-rate in patients affected by LUTS/BPH. Other combination therapies, such as with tamsulosin, [48][49][50] Urtica dioica, 39 Pinus pinaster 36 and Peucedanum japonicum, 51 have also shown positive results in co-prescriptions for treating BPH and BPH-linked disorders.…”

Section: Clinical Application Of Spe In Urinary System Diseasesmentioning

confidence: 99%

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

Yin

Wang

et al. 2021

Natural Product Communications

View full text Add to dashboard Cite

Saw palmetto extract (SPE) has been widely used as a therapeutic remedy for urinary dysfunction in western countries. Furthermore, as an herb drug, it can be used as an alternative therapy for benign prostatic hyperplasia (BPH) due to its safety and minimum adverse effects. Reportedly, SPE improves the urinary symptoms, which mainly depend on anti-androgenic effects and effects on autonomic receptors in the lower urinary tract. However, the mechanisms of action responsible for the therapeutic roles of SPE have not been fully elucidated. Relevant studies indicate that SPE has some positive effects on the treatment of urological diseases in animals, and clinical trials are ongoing. In this review, we summarize the pharmacological properties and discuss the possible therapeutic mechanisms of SPE in urological diseases, including anti-androgenic effects, effects on autonomic receptors in the lower urinary tract, anti-inflammatory activity, anti-proliferative and pro-apoptotic effects, and highlight a potential therapeutic approach in the clinical treatment of patients with BPH, prostate cancer, chronic prostatitis (CP) and erectile dysfunction (ED).

show abstract

“…In this scenario, an increasing interest on the role of phytotherapeutic and nutraceutical agents either as alternative or in addition to conventional therapy for the management of BPH has evolved during the last decades [7][8][9]. Particularly, if on the one hand Serenoa repens (SeR) represents nowadays one of the most promising extracts [10], on the other hand several recent clinical trials assessed its effectiveness and safety as first-line approach as monotherapy or in combination with other nutraceutical elements such as selenium (Se) and lycopene (Ly) [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Impact of the Treatment of Serenoa repens, Solanum lycopersicum, Lycopene and Bromelain in Combination with Alfuzosin for Benign Prostatic Hyperplasia. Results from a Match-Paired Comparison Analysis

Lambertini

Maida

Tellini

et al. 2021

Uro

Self Cite

View full text Add to dashboard Cite

Background: Phytotherapeutic agents aroused an increasing interest either as alternative or in addition to conventional therapy in the management of BPH. The aim of the article was to evaluate the clinical and functional changes after add-on treatment with Serenoa repens associated with Solanum lycopersicum, lycopene and bromelain in patients with BPH presenting with mild to moderate LUTS and previously treated only with Alfuzosin over a 6–12 months period. Materials and methods: Between January and July 2019, patients with symptomatic BPH already on treatment with Alfuzosin (Al) 10 mg for at least 6–12-month were enrolled at three academic referral centres, included in a prospective treatment group, and managed with a combination treatment of Al and 6-month daily oral single-tablet supplementation of Serenoa repens and Solanum lycopersicum + lycopene + bromelain (SeR + SL + Ly + Br). A retrospective control group with comparable baseline characteristics was obtained by performing a propensity score matching from a database of 434 patients managed with Alfuzosin 10 mg/day only over a 6–12 months period between March 2015 and December 2018. IPSS, QoL questionnaires, voiding diary assessment, postvoid residual volume (PVR), maximal (Qmax) and average (Qave) urinary flow rates were evaluated at baseline in the treatment group at the moment of patient accrual, in the control group after 6-month of treatment with alfuzosin, and thereafter at 3 and 6 months in both groups. Results: Overall, 250 patients entered the study (n = 125 treatment group; n = 125 control group). Total IPSS score significantly decreased at 6-month assessment from baseline in the treatment vs control group (17 [IQR: 12–20] vs 12 [IQR: 9–14], p = 0.02) with a significative storage symptoms improvement detected both at 3- (p = 0.03) and 6-month evaluation (p = 0.001). PVR significantly improved at each follow-up visit with the most relevant reduction at 6-month assessment (125 cc vs. 102 cc; p = 0.02). Moreover, a significative improvement in LUTS-related quality of life (QoL) was recorded at 3- and 6-month assessment with a median decrease of −1 and −2 (p = 0.05 and p = 0.001 respectively) from baseline. Conclusions: Combination treatment with AB and SeR + SL + Ly + Br led to meaningful improvements in LUTS severity compared to AB as monotherapy, after a 6-month treatment period in men with mild to moderate LUTS/BPH.

show abstract

A Prospective, Open-Label Comparison of Tamsulosin plus <b><i>Serenoa repens</i></b> and Bovine Colostrum versus Tamsulosin Alone in the Treatment of Benign Prostatic Hyperplasia

Cited by 5 publications

References 19 publications

Saw Palmetto Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Assessment in Iraq

Saw Palmetto Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Assessment in Iraq

The Therapeutic Potential of Saw Palmetto Extract in Urological Disorders

Impact of the Treatment of Serenoa repens, Solanum lycopersicum, Lycopene and Bromelain in Combination with Alfuzosin for Benign Prostatic Hyperplasia. Results from a Match-Paired Comparison Analysis

Contact Info

Product

Resources

About